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Introduction
Epithelial ovarian cancer represents the most frequent cause of 
death among women with gynecological malignancies, primar-
ily due to the fact that symptoms generally occur when an ad-
vanced stage of disease has been reached, but also due to mis-
understanding of the general standard of care and therapeutic 
approach. Worldwide, approximately 200.000 women are diag-
nosed with this pathology and more than half will die in spite of 
new surgical and chemotherapeutic protocols available (Schorge 
et al 2008). More than 90% of cases are epithelial tumors, in-
cluding borderline masses. Epithelial ovarian cancer is unique 
compared to other solid malignant tumors, in that it originates 
at the surface epithelium rather than the parenchimatous area 
of the organ. The rest of the 10% originate either in the germi-
native ovarian cells or are stromal tumors (Dutta et al 2010). 
The clinical onset of the disease is non-specific and allows for 
confusion with many benign diseases, especially digestive and 
urological. Optimal debulking surgery remains the only effec-
tive treatment with which long-term disease free intervals and 
cure can be achieved and remains the most important survival 
prognostic factor for ovarian cancer. While at some point a re-
sidual disease less than 1 cm, even 2 cm was accepted as optimal 
surgical treatment, currently, the standard of care requires that 
no microscopic disease is present after cytoreductive surgical 
treatment. No gross residual disease is associated with improved 
overall survival, and radical surgery is effective for achieving 
this (Chang et al 2012). 
Several epidemiological studies on ovarian cancer exist, gen-
erally showing similar results, while retrospective reports have 
almost consistently demonstrated that age, performance status, 
histological grade and subtype, clinical stage and size of resid-
ual disease are independent prognostic factors (Skírnisdóttir et 
al 2007). Furthermore, prospective randomized phase III trials 
have showed that platinum-based chemotherapy, especially 
when combined with paclitaxel, was associated with a higher 
response rate and median survival compared with other regi-
mens (Piccart et al 2000).
The global risk for a patient to develop ovarian cancer through-
out their lifetime is 1,8% (Dutta et al 2010). There is no effec-
tive screening method and the clinical presentation is scarce 
and non-specific. Consequently, more than 75% of cases are 
diagnosed in an advanced stage (FIGO III/IV). Despite some 
improvement of median survival due to the development of 
primary surgical procedures and chemotherapy protocols, the 
percentage is relatively constant around 30%. Alternatively, 
women diagnosed in the first stages of disease will not only un-
dergo much less aggressive surgery, but will also have a 90% 
5-year survival rate and better quality of life. Unfortunately, 
the high percentage of patients diagnosed in advanced stages 
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underlines the lack of efficiency of pelvic examination (which 
is notably inaccurate in detecting subtle changes in ovarian size 
and morphology, particularly in postmenopausal women) and 
imaging techniques in confirming incipient disease. This calls 
for a standardization not only of treatment but also diagnostic 
protocols used, especially in patients at high risk for develop-
ing this disease. Biochemical diagnostic tools (CA-125 and the 
ROMA/ROCA score) have emerged as the investigations with 
the highest sensitivity and specificity used to refer patients at 
high risk to further investigation. The diagnostic protocol re-
quires using an imaging technique to complete pelvic examina-
tion and characterization of pelvic masses (Transvaginal ultra-
sound, gray-scale or contrast enhanced, CT/MRI). 
More recently, focus is shifting on the importance of treatment 
center and surgical team in the outcome of ovarian cancer care, 
with some countries developing referral guidelines that recom-
mend that ovarian cancer patients be treated in specialized cent-
ers because treatment in such hospitals has been shown to re-
sult in better survival. Furthermore, general gynecologists with 
a special interest in gynecologic oncology, who operate on all 
patients with ovarian cancer in their clinic and work with gy-
necologic oncologists from regional specialized centers, might 
also provide adequate care to ovarian cancer patients (Vernooij 
et al 2008).
Epithelial ovarian cancer in Romania has not been adequately 
studied (except for prospective clinical trials) probably because 
of the lack of electronic medical records and a central regsitry of 
patient data, making them practically inaccessible to research-
ers. The Oncology Institute “Prof. Dr. Ion Chiricuta” holds a 
consistent archive of patient data, cases that have been referred 
to, diagnosed or treated in this hospital, representing an invalu-
able source of information. 
The aim of this study was to present the demographic, patho-
logical, clinical features (symptoms and diagnosis method) and 
treatment protocol and outcome of patients with ovarian cancer. 
Materials and method
From January 2007 to December 2007, 251 patients had been 
diagnosed and treated for ovarian cancer within the Oncology 
Institute “Prof. Dr. Ion Chiricuta” Cluj-Napoca. The cancer di-
agnosis was histologically documented by expert pathologists 
and cytopathologists from referral centers with experience in 
gynecological malignancies. From the patient base, only those 
files with written consent for participation in research studies 
were analyzed, thus remaining 89 eligible cases for statistical 
analisys. These files were analyzed within the archive of the 
Oncology Institute “Prof. Dr. Ion Chiricuta”.
Demographic data consisted of: source environment, age, par-
ity, menarche and menopause onset age, performance index at 
diagnosis and associated pathology. For every patient studied, 
we documented the diagnosis protocol used (clinical and/or im-
agistical methods) for initial diagnosis and also for follow up 
of patients that were continuously referred to our center after 
therapy. We made a record of main clinical symptoms upon re-
ferral for all patients included in our study. Tumor characteri-
zation included histological subtype, tumour grading and stage 
at diagnosis. Surgical reports were collected for all the patients 
and the type of operation and extent of residual disease were 
recorded, as well as the chemotherapy protocol administered 
and response obtained. 
This patient base is part of an extensive 5-year retrospective 
study underway at our center, with prognostic correlations to 
be published with our final results. 
The statistical processing of data was performed using Medcalc 
Software version 12.7. Quantitative variables were tested for 
normality of distribution using Kolmogorov-Smirnov test. Non-
normally distributed variables were described using the median 
and range. Nominal and ordinal variables were characterized 
by frequency and percentage.   
Results
The basic patient characteristics are illustrated in Table 1. The 
median age at diagnosis was 52 years, with approximately 80% 
of patients having a good performance status. Of the most com-
mon associated pathologies found, obesity and hypertension 
were among the most frequent ones (found in 12% and 32% of 
patients respectively).
Table 1. Basic patient characteristics
Of the paraclinical methods used for initial diagnosis, a clinical 
pelvic examination by a gynecologist and a pelvic ultrasound 
were most commonly used, with over 50% of patients undergo-
ing these examinations. However, biochemical evaluation (CA 
125) was only used in 27% of patients and in approximately 
one third of patients diagnosis was unexpected, during surgery 
for another pathology (suspected benign gynecologic tumors 
or acute surgical pathology).
After treatment follow-up included ultrasound examinations in 
more than 90% of patients, CA 125 in 70% of cases, and CT 
Median Range
Age 52.4 22-77
Age at menarche 13.7
Age at menopause 46.4
N %
Source environment
Urban 46 51.7
Rural 43 48.3
Parity
Nuliparous 10 11.3
Multiparous 78 88.7
PS (performance status)
0 36 40.4
1 38 42.6
2 14 15.7
3 1 1.1
Associated pathology
Obesity 11 12.3
Hypertension 29 32.6
Diabetes mellitus 8 8.9
Hyperlipidemia 6 6.7Maxim et al 2013
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scans in 60%. Only 4,5% of patients did not report for follow-
up in our center. 
Tabel 2. Initial and follow-up diagnosis methods
Clinical onset was scarce and non-specific, abdominal pain and 
discomfort being the reason for seeking medical help in almost 
70% of patients. Gynecologic symptoms (vaginal bleeding) 
were only found in 12% of cases, the rest presenting with diges-
tive or urinary symptomatology, or for weight loss and fatigue. 
Table 3. Clinical characteristics of patients
The majority of cases (more than 85%) were epithelial ovar-
ian tumors, with a total of approximately 70% grade 2 and 3. 
More than 50% of patients were diagnosed in stages II and IV 
of disease. 
Of the patients that underwent surgery in our center, more than 
70% were left with no macroscopic residual disease, and approx-
imately 13% with residual disease of 2 cm or more. Complete 
response after adjuvant therapy was obtained in more than 65% 
of cases, and no response after therapy in 11%. 
Discussions
The mainly descriptive nature of this study points out certain 
important characteristics of the case population. Ovarian cancer 
patients in our region are most often inappropriately investigated 
Table 4. Tumor characterization
Table 5. Treatment completion and response
prior to a surgical intervention and methods with a screening 
utility such as transvaginal ultrasound and CA-125 are only used 
in approximately one third to one half of patients suspect of pel-
vic masses. Standardization of pre-treatment care could lead to 
a better and earlier diagnosis of patients with malignant ovarian 
tumors, and patients with suggestive symptoms (non-specific as 
they may be, in context of a menopausal woman with risk fac-
tors for ovarian cancer can be suggestive) should be referred to 
centers where diagnostic methods are more widely available.
The importance of treatment center is obviously pointed out 
when analyzing the large statistical difference between pre-
treatment and follow-up investigations. Initial diagnosis is still 
made in more than 50% of patients in an advanced stage (III or 
IV). On the other hand, after patients have been referred to a 
cancer-specialized center, the use of standard-of-care methods 
is increased (up to 90% of patients underwent recommended 
investigations for treatment monitoring).  
The standard treatment of epithelial ovarian cancer at all clini-
cal stages is currently debulking surgery (Akahira et al 2001, 
Oksefjell et al 2007, Winter et al 2007, 2008). Patients subjected 
to total abdominal hysterectomy + bilateral salpingo-oophorec-
tomy + omentectomy + retroperitoneal lymph node sampling 
have a survival benefit compared to those not treated according 
to the standard surgical procedure. Optimal debulking results 
N %
Initial diagnosis method
Pelvic exam 50 56.1
Ultrasound 51 57.3
CA 125 24 26.9
Incidental  24 26.9
Follow-up 
Ultrasound 82 92.1
CT scan 56 62.9
CA 125 64 71.9
Basic lab work-up 38 42.6
No follow-up 4 4.5
N %
Main clinical symptoms
Pain and abdominal discomfort 60 67.4
Digestive symptoms (nausea, vomiting, 
loss of appetite) 16 18
Weight loss 8 9
Fatigue 9 10
Urinary symptoms 8 9
Vaginal bleeding 11 12.3
Number of symptoms
0 24 26.9
1 32 35.9
2 19 21.3
3 14 15.7
N %
Histology
Epithelial tumors 76 85.3
Sex-cord stromal tumors 4 4.5
Germinative-cell tumors 3 3.3
Borderline tumors 6 6.7
Metastatic tumors 1 1.1
Grading 
G1 15 16.8
G2 37 41.5
G3 28 31.4
Stage at diagnosis
I 36 40.4
II 5 5.6
III 43 48.3
IV 5 5.6
N %
Residual disease
R0 64 71.9
R1 10 11.2
R2 12 13.4
Response after adjuvant therapy
RC 59 66.2
RP 10 11.2
BEV 10 11.2Maxim et al 2013
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in our study were quite high (over 70%), concordant to current 
literature results, showing a proper affiliation to current treat-
ment standards with good results. The goal of every cytore-
ductive procedure should be to debulk the cancer to no visible 
disease. In addition, several studies suggest that lymphadenec-
tomy, especially in those who have all disease resected, may 
improve outcomes (du Bois et al 2010). Additionally, surgical 
specialization has been associated with higher rates of optimal 
cytoreduction, appropriate surgical care and survival (Goff et al 
2007, Engelen et al 2007, Vergote et al 2010). Whenever possi-
ble, a gynecologic oncologist should be involved in the surgical 
management of all women with ovarian cancer. In general, with 
gynecologic oncology involvement approximately 60-70% of 
patients will be able to be optimally cytoreduced using the new 
definition of no visible residual disease. 
While the finding that most cases were epithelial ovarian tumors 
is not surprising, as this is the case in most populations stud-
ied, however we found an increased number of patients (over 
70%) with a poor histological grading (G2 or G3) that more of-
ten correlates with a poor response to chemotherapy and short 
disease-free interval.
Clinical onset, while scarce and misleading, can still be sug-
gestive, and any female patient (especially after menopause) 
presenting with abdominal discomfort, change in appetite or 
other digestive symptoms should be referred to a gynecolo-
gist for examination to exclude the presence of a pelvic mass. 
Upon completion of our study series, we hope to analyze the 
correlation between prognostic factors and disease free intervals 
and also focus on the impact proper diagnosis and follow-up 
have on patient evolution after treatment and on disease stage 
upon diagnosis, and also have a proper characterization of pop-
ulation at risk in our region. 
Conclusions
In conclusion, this report provides a great deal of information 
about basic patient characteristics, diagnosis and follow-up 
tools, surgical conduct and treatment results and points out ar-
eas where standardisation and improvement of care is required.
Acknowledgements
We would like to aknowledge The Oncology Institute „Prof. Dr. 
Ion Chiricuta” Cluj-Napoca for providing us with the valuable 
patient files stored in the institutuions archive.
This study was supported by research grant POSDRU                           
107/1.5/S/78702, project cofinanced from European Social 
Fund  by Sectorial Operational Program for Human Resources 
Development 2007-2013.
References
Akahira, J. I., Yoshikawa, H., Shimizu, Y., et al, 2001. Prognostic fac-
tors of stage IV epithelial ovarian cancer: a multicenter retrospec-
tive study. Gynecol Oncol 81: 398-403. 
du Bois, A., Reuss, A., Harter, P., et al, 2010. Potential role of lym-
phadenectomy in advanced ovarian cancer: a combined exploratory 
analysis of three prospectively randomized phase III multicenter tri-
als. J Clin Oncol 28:1733–1739.
Chang, S. J., Bristow, R. E., Ryu, H. S., 2012. Impact of complete cy-
toreduction leaving no gross residual disease associated with radical 
cytoreductive surgical procedures on survival in advanced ovarian 
cancer. Ann Surg Oncol 19(13):4059-67.
Dutta, S., Wang, F. Q., Fleischer, A. C., et al, 2010. New Frontiers for 
Ovarian Cancer Risk Evaluation: Proteomics and Contrast-Enhanced 
Ultrasound. American Journal of Roentgenology 194:349-354.
Engelen, M. J., Kos, H. E., Willemse, P. H., et al, 2006. Surgery by 
consultant gynecologic oncologists improves survival in patients 
with ovarian carcinoma. Cancer 106:589–598.
Goff, B. A., Matthews, B. J., Larson, E. H., et al, 2007. Predictors of 
comprehensive surgical treatment in patients with ovarian cancer. 
Cancer 109:2031–2042.
Oksefjell, H., Sandstad, B., Trope, C., 2007. Improved survival for 
stage IIIC ovarian cancer patients treated at the Norwegian Radium 
Hospital between 1984 and 2001. Eur J Gynaecol Oncol 28: 256-262.
Piccart, M. J., Bertelsen, K., James, K., et al, 2000. Randomized inter-
group trial of cisplatin-paclitaxel vs. cisplatin-cyclophosphamide in 
women with advanced epithelial ovarian cancer: three-year results. 
J Natl Cancer Inst 92:699-708.
Schorge, J. O., Schaffer, J. I., Halvorson, L.M., et al, 2008. Williams 
Gynecology. McGraw-Hill.
Skírnisdóttir, I., Sorbe, B., 2007. Prognostic factors for surgical outcome 
and survival in 447 women treated for advanced (FIGO-stages III-
IV) epithelial ovarian carcinoma. Int J Oncol 30:727-734.
Vergote, I., Trope, C. G., Amant, F., et al, 2010. Neoadjuvant chemo-
therapy or primary surgery in stage IIIC or IV ovarian cancer. N 
Engl J Med 363:943–953.
Vernooij, F., Heintz, P. M., Witteveen, P. O., et al, 2008. Specialized 
care and survival of ovarian cancer patients in The Netherlands: 
Nationwide cohort study. J Natl Cancer Inst 100(6):399-406.
Winter, W. E. III, Maxwell, G. L., Tian, C., et al, 2007. Prognostic fac-
tors for stage III epithelial ovarian cancer: a Gynecologic Oncology 
Group Study. J Clin Oncol 25:3621-3627.
Winter, W. E. III, Maxwell, G. L., Tian, C., et al, 2008. Tumor residu-
al after surgical cytoreduction in prediction of clinical outcome in 
stage IV epithelial ovarian cancer: a Gynecologic Oncology Group 
Study. J Clin Oncol 26:83-89.
Authors
•Anita-Roxana Maxim, Department of Obstetrics and Gynecology 
II, “Iuliu Haţieganu” University of Medicine and Pharmacy,   
57th 21st Decembrie 1989 Boulevard, 400124, Cluj-Napoca, 
Cluj, România, email: anitamercea@yahoo.com
•Camelia A. Coadă, “Iuliu Haţieganu” University of Medicine 
and Pharmacy, 8th Victor Babeş Street, 400012, Cluj-Napoca, 
Cluj, Romania, EU, email: camelia.coada@gmail.com
Radu I. Badea, Regional Gastroenterology and Hepatol-
ogy Institute “Prof Dr. Octavian Fodor”, “Iuliu Haţieganu” 
University of Medicine and Pharmacy, 5th Constanta Street, 
Cluj-Napoca, Cluj, România, email: rbadea@umfcluj.roMaxim et al 2013
Volume 5 | Issue 3 Page 113 
HVM Bioflux
http://www.hvm.bioflux.com.ro/
Citation
Maxim, A.-R., Coadă, C. A., Badea R. I., 2013. Ovarian cancer experience from a 
Romanian regional center: preliminary results. HVM Bioflux 5(3):109-113. 
Editor Ştefan C. Vesa
Received 25 September 2013
Accepted 10 November 2013
Published Online 10 November 2013
Funding Research grant POSDRU 107/1.5/S/78702
Conflicts/ 
Competing 
Interests
None reported